Compounds and uses thereof to induce an immunogenic cancer cell death in a subject

A method of selecting an optimal therapeutic treatment of cancer in a subject having a tumor, said method comprising assessing the sensitivity of the subject to a first treatment of cancer and, if the subject is resistant to said first treatment of cancer, a step of selecting (i) a product allowing or enhancing the secretion of HMGB1 and/or promoting ATP release (ii) a product promoting activation of the TLR4/myd88 pathway, or able to bypass said pathway, (iii) a product stimulating the autophagy machinery, and (iv) any combination thereof, to be used in combination with the first treatment of cancer as the optimal therapeutic treatment of cancer for the subject, wherein said assessing the selectivity of the subject comprises:

• a) determining the ability of the tumor to induce an anticancer immune response, said step comprising verifying the expression by tumor cells of nuclear HMGB1, wherein the absence of nuclear HMGB1 in tumor cells is indicative of the inability of the tumor to induce an anticancer immune response and wherein the inability of the tumor to induce an anticancer immune response is indicative of a resistance of the subject to the treatment of cancer, and wherein, on the contrary, the presence of nuclear HMGB1 in tumor cells is indicative of the ability of the tumor to induce an anticancer immune response and wherein the ability of the tumor to induce an anticancer immune response is indicative of the subject's sensitivity to the treatment of cancer;
• b) determining the ability of the tumor to induce an anticancer immune response, said step comprising verifying the expression by tumor cells of nuclear HMGB1, wherein the absence of nuclear HMGB1 in tumor cells is indicative of the inability of the tumor to induce an anticancer immune response and wherein the inability of the tumor to induce an anticancer immune response is indicative of a resistance of the subject to the treatment of cancer, and wherein, on the contrary, the presence of nuclear HMGB1 in tumor cells is indicative of the ability of the tumor to induce an anticancer immune response and wherein the ability of the tumor to induce an anticancer immune response is indicative of the subject's sensitivity to the treatment of cancer, wherein the step of determining the ability of the tumor to induce an anticancer immune response further comprises verifying the expression by tumor cells of cytosolic microtubule-associated protein 1 light chain 3 (LC3), in particular of LC3-II, wherein the absence of cytosolic LC3 in tumor cells is indicative of the inability of the tumor to induce an anticancer immune response, and wherein, on the contrary, the presence of cytosolic LC3 in tumor cells is indicative of the ability of the tumor to induce an anticancer immune response;
• or
• c) determining the ability of the tumor to induce an anticancer immune response, said step comprising verifying the expression by tumor cells of nuclear HMGB1, wherein the absence of nuclear HMGB1 in tumor cells is indicative of the inability of the tumor to induce an anticancer immune response and wherein the inability of the tumor to induce an anticancer immune response is indicative of a resistance of the subject to the treatment of cancer, and wherein, on the contrary, the presence of nuclear HMGB1 in tumor cells is indicative of the ability of the tumor to induce an anticancer immune response and wherein the ability of the tumor to induce an anticancer immune response is indicative of the subject's sensitivity to the treatment of cancer, wherein the step of determining the ability of the tumor to induce an anticancer immune response further comprises verifying the expression by tumor cells of ecto-nucleoside-triphosphate-diphosphohydrolase (CD39) and/or of the ectonucleotidase CD73, and wherein the presence of CD39 and/or CD73 is indicative of the inability of the tumor to induce an anticancer immune response.